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Background:Our previous studies showed that the direct injection of an adenovirus construct expressing urokinase-type plasmin-
ogen activator (uPA) into experimental venous thrombi significantly reduces thrombus weight. The systemic use of adenovirus
vectors is limited by inherent hepatic tropism and inflammatory response. As macrophages are recruited into venous thrombi, it is
reasonable to speculate that these cells could be used to target the adenovirus uPA (ad-uPA) gene construct to the thrombus. The
aims of this studywere to determinewhethermacrophages transducedwith ad-uPAhave increased fibrinolytic activity andwhether
systemic injection of transduced cells could be used to target uPA expression to the thrombus and reduce its size.
Methods: The effect of up-regulating uPA was examined in an immortalized macrophage cell line (MM6) and macrophages
differentiated from human blood monocyte-derived macrophages (HBMMs). Cells were infected with ad-uPA or blank control
virus (ad-blank). Fibrinolytic mediator expression, cell viability, and cytokine expression were measured by activity assays and
enzyme-linked immunosorbent assays. Monocyte migration was measured using a modified Boyden chamber assay. A model of
venous thrombosiswas developed and characterized inmicewith severe combined immunodeficiency (SCID).Thismodelwas used
to studywhether systemically administeredmacrophages over-expressing uPA reduced thrombus size.Uptake ofHBMMs into the
thrombus induced in these mice was confirmed by a combination of PKH2-labeled cell tracking and colocalization with human
leukocyte antigen (HLA) by immunohistology.
Results:Comparedwith ad-blank, treatedHBMMs transductionwith ad-uPA increased uPA production by>1000-fold (P
.003), uPA activity by 150-fold (P .0001), and soluble uPA receptor (uPAR) by almost twofold (P .043). Expression of
plasminogen activator inhibitor (PAI-1) and PAI-2 was decreased by about twofold (P  .011) and threefold (P  .005),
respectively.Up-regulation of uPAhadno effect on cell viability or inflammatory cytokine production comparedwith ad-blank
or untreated cells. Ad-uPA transduction increased the migration rate of HBMMs (about 20%, P  .03) and MM6 cells
(>twofold, P  .005) compared with ad-blank treated controls. Human macrophage recruitment into the mouse thrombus
was confirmed by the colocalization of HLA with the PKH2-marked cells. Systemic injection of uPA-up-regulated HBMMs
reduced thrombus weight by approximately 20% compared with ad-blank (P  .038) or sham-treated controls (P  .0028).
Conclusion: Transduction of HBBM with ad-uPA increases their fibrinolytic activity. Systemic administration of uPA
up-regulated HBBMs reduced thrombus size in an experimental model of venous thrombosis. Alternative methods of
delivering fibrinolytic agents are worth exploring. (J Vasc Surg 2009;50:1127-34.)
Clinical Relevance: The use of thrombolysis in the treatment of acute iliofemoral deep vein thrombosis is not suitable for all
patients. Our previous studies have shown that direct injection of an adenovirus construct expressing urokinase plasminogen
activator (uPA) into experimental venous thrombi significantly reduced thrombus weight. The systemic use of adenovirus
vectors is, however, limited by both their inherent hepatic tropism, which precludes targeted delivery to disease sites, and by
the associated host inflammatory response. As macrophages are recruited into venous thrombi, these cells could be used to
target uPA gene constructs to the thrombus after systemic administration.The changes that lead to post-thrombotic syndrome are
caused by a combination of valvular damage and persistent
venous outflow restriction. Rapid recanalization of veins pre-
serves valve integrity and is associated with a lower incidence
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tion, which reduces the risk of pulmonary embolism, pre-
vents thrombus propagation, and allows slow natural reso-
lution.3 Anticoagulants do not, however, promote natural
resolution and can cause bleeding complications. Throm-
bolytic agents and thrombectomy remove thrombus rap-
idly in some patients who are treated early but their use is
limited.4 Novel strategies that replace or augment antico-
agulation and hasten thrombus resolution without the risk
of hemorrhage are therefore attractive. Natural thrombus
resolution is regulated by an inflammatory response involv-
ing the recruitment of neutrophils and monocytes, fol-
lowed by endothelial cells and myofibroblasts, leading to
thrombus organization, contraction, and recanalization of
the vein lumen.5
There is a progressive increase in plasminogen activator
(PA) activity within the thrombus as organization proceeds
that appears to be associated with the influx of monocytes6
that are recruited into the thrombus in a temporal pattern.7
The fibrinolytic system is an important mediator of cell
migration and tissue remodelling.8 Net fibrinolytic activity
is the product of the relative abundance of PAs and their
inhibitors, PAI-1 and PAI-2.9
Deletion of the gene encoding the urokinase-type plas-
minogen activator (uPA) prevents thrombus resolution,
and this is associated with a marked reduction in monocyte
ingress into the thrombus.10 These findings have led to the
hypothesis that monocyte recruitment, regulated through
the expression of uPA, is an essential mechanism in throm-
bus resolution.
Direct injection of an adenovirus construct expressing
uPA (ad-uPA) into experimental venous thrombi signifi-
cantly reduces thrombus weight.11 The systemic use of
adenovirus vectors, however, is limited by their inherent
hepatic tropism, which precludes targeted delivery to alter-
native organs or disease sites, and by the host inflammatory
response.12 As monocytes are recruited into venous thrombi,
it would be reasonable to speculate that these cells could be
used to target the ad-uPA gene construct to the thrombus
after systemic administration. The aims of this study were
therefore to determine whether monocytes transduced with
ad-uPA have increased fibrinolytic activity and whether sys-
temic injection of transduced cells could be used to target
uPA expression to the thrombus and reduce its size.
MATERIALS AND METHODS
Permission to conduct these studies was obtained from
St Thomas’Hospital Ethics Committee. Serotype-5 adeno-
viral vectors encoding human uPA (ad-uPA)13 and an
empty cassette (ad-blank) were used. Adenovirus was am-
plified in human embryonic kidney cells (HEK-293), and
purified and titered using the AdenoX system (Becton
Dickinson, Franklin Lakes, NJ).
Transduction of human blood monocyte-derived
macrophages. Pure (90%) monocyte preparations were
isolated from blood using Optiprep (Axis-Shield, Cam-
bridgeshire, UK).14 Isolated cells were resuspended in Ro-
swell Park Memorial Institute media (Sigma Aldrich, Dor-set, UK) supplemented with 10% fetal calf serum (Life
Technologies, Paisley, UK) and 2 mM glutamine (Sigma).
Monocytes/macrophages are resistant to adenovirus infec-
tion.15 Cells were therefore cultured for 72 hours with
100-ng/mL monocyte colony-stimulating factor (MCSF;
R&D Systems, Abingdon, UK) to up-regulate integrins,
which facilitate adenoviral infection. Cells were treated with
the adenovirus or culture media alone (baseline control) at
a multiplicity of infection (MOI) of up to 2500 and har-
vested after 4 days. Cell viability was assessed by measuring
lactate dehydrogenase (LDH; Promega, Southampton, UK)
and caspase-3 activity (Sigma) in conditioned media.
Confirmation of human blood monocyte-derived
macrophages transduction. Urokinase upregulation was
confirmed before use in all studies as follows:
● uPA fibrin plate analysis: A fibrin gel was formed using
fibrinogen (0.4%, Sigma), agarose (0.15%, Sigma), and
lys-plasminogen (25 g/mL) in phosphate-buffered
saline (pH 7.4; Sigma). Fibrin cross-linkage was in-
duced by the addition of thrombin (5 IU/mL). Con-
ditioned media and active uPA standards were added
and incubated for 12 hours at 37°C.
● uPA S2444 substrate activity assay: Urokinase (uPA)
activity was measured using a colorimetric assay.16
Fibrinolytic activity and inflammatory mediator ex-
pression after adenovirus transduction. Monocytes were
isolated from 12 donors and transfected with 1000MOI of
ad-uPA, ad-blank, or carrier alone (baseline control). Lev-
els of uPA activity and uPA antigen were measured in
human blood monocyte-derived macrophages (HBMM)-
conditioned media using a colorimetric assay16 and enzyme-
linked immunosorbent assay (ELISA),17 respectively. The
levels of PAI-1,18 PAI-2,19 soluble uPA receptor (uPAR,
R&D Systems), tissue plasminogen activator (tPA; gift,
Prof. P. J. Declerck, Leuven, Belgium), and monocyte
chemotactic protein-1 (MCP-1, R&D Systems) were mea-
sured by ELISA. Tumour necrosis factor- (TNF-), reg-
ulated upon activation normal T-cell expressed and se-
creted (RANTES), interferon- (IFN-), interleukin-1
(IL-1), IL-1, IL-4, IL-6, IL-8, IL-10, and granulocyte
macrophage-colony stimulating factor (GM-CSF) were
measured using the Beadmaster system (Upstate, USA,
Millipore, Billerica, Mass).
Ad-uPA transduction and monocyte migration in
vitro. Amacrophage cell line, MM6 (gift, Professor Ziegler-
Heitbrock, Munich, Germany), and HBMMs were trans-
fected with 1000MOI of ad-uPA or ad-blank as described.
Cell migration was assessed using amodified Boyden cham-
ber.20 Cells were fluorescently labeled with Calcein AM
(Invitrogen, Paisley, UK).
Filter inserts (3-m pore size, Fluoroblok; BD Bio-
sciences, Becton Dickinson, Franklin Lakes, NJ) were
coated in fibrin gel to a depth of 1 mm. Macrophages (5
105 cells) were added to the upper chamber, and MCP-1
(300 ng/mL, R&D Systems) or carrier was added to the
lower chamber. Fluorescence was measured over 150
minutes (VictorLight; Perkin-Elmer, Salem, Mass).
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MM6 cells and in triplicate with HBMMs. The data were
expressed as the percentage of maximal fluorescence ob-
tained from the total number of labeled cells used.
Severe combined immunodeficiency mouse model
of venous thrombosis. UK Home Office approval was
obtained for all animal procedures. Thrombosis was in-
duced in the inferior vena cava of severe combined immu-
nodeficiency (SCID) mice using reduced flow and endo-
thelial disturbance.10,11 Thrombi were harvested at 1, 7, 14
and 21 days after induction. Paraffin sections (5 m) were
taken at 300-m intervals throughout the whole length of
the thrombus. The area of thrombus over a defined length
gives an approximation of thrombus volume.10 Thrombus
and recanalization areas were measured in sections stained
with hematoxylin and eosin using image analysis.21
Neutrophil ingress (identified by nuclear morphology)
was assessed in hematoxylin and eosin sections taken from
1-day-old thrombi. Lymphocytes were stained with anti-
CD3, a T-cell marker, and anti-CD79a, a B-cell marker
(both Abcam, Cambridge, UK).
Monocyte ingress occurs at a later stage.7 Sections from
7- and 14-day thrombi were therefore stained with the
mouse monocyte marker MAC3 (BD Pharminogen, Bec-
ton Dickinson, Franklin Lakes, NJ). Primary antibody
binding was located using biotinylated secondary antibod-
ies and the ABC-peroxidase complex (Vector Laboratories,
Peterborough, UK). Matched isotype or polyclonal immu-
noglobulin from the appropriate species acted as controls.
Twenty sections of each thrombus were evaluated for each
stain or control. Staining was quantified by image analysis
and calculated as a mean percentage of the total area.
Tracking of HBMMs injected into SCID mice.
HBMMs were isolated and labeled with PKH2 fluorescent
cell marker as previously described.22 Labeled cells (6.5 
105) were injected into the tail vein of the SCID mouse 2
hours before thrombus formation. The thrombi were re-
moved after 7 days. PKH2 green fluorescence was colocal-
ized with the binding of a red fluorescently labeled anti-
human leukocyte antigen (HLA) antibody (Serotec,
Kidlington, UK). Primary antibody was detected with an
Table I. Expression of fibrinolytic mediators by primary h
ad-uPA and ad-blank and baseline cells treated with carrier
Variablesa Ad-uPA A
uPA antigen, ng/mg sol protein 1122 (297) 0.0
uPA activity, IU/mL 148 (14) 0.
uPAR, ng/mg sol protein 6684 (2300) 401
PAI-1, ng/mg sol protein 17 (5) 2
PAI-2, ng/mg sol protein 2285 (661) 491
Ad, Adenovirus; NS, not significant; PAI, plasminogen activator inhibito
activator receptor.
aData are expressed as mean (standard error of the mean) of 12 healthy indantimouse Alexa 568 conjugated secondary antibody(Cambridge Biosciences, Cambridge, UK). An isotype-
matched antibody was used as a negative control.
The effect of uPA up-regulation in HBMMs on
thrombus resolution. HBMMs (1  106 cells) were
transfected with 2500 MOI of ad-uPA or ad-blank and
injected 2 hours before thrombus formation into the tail
vein of two cohorts of eight mice. A third cohort of eight
animals was injected with carrier containing no cells. The
thrombi were harvested 7 days after induction, in a blinded
manner. At 7 days, the model thrombus in untreated
controls is still occlusive but beginning to organize; there-
fore, any effect of treatment would be expected to be
maximal at this point.23
Statistical analysis. Values were expressed as mean 
standard error (SEM). Two-way analysis of variance
(ANOVA) was used to compare the temporal changes in
thrombus resolution in the SCID model and wild-type
controls. Paired and unpaired t tests were used for compar-
isons of parametric data and Wilcoxon or MannWhitneyU
tests were applied to nonparametric data.
RESULTS
HBMM fibrinolytic mediator production and cyto-
kine response after ad-uPA transduction. Ad-uPA trans-
duction increased HBMM fibrinolytic activity by 150-fold
(P  .0001) compared with ad-blank–treated controls
(Table I). Production of uPA antigen was increased from
the lower limit of detection of the uPA ELISA by 1000-
fold (P  .003, Table I). No tPA antigen or activity could
be measured in treated HBMMs. Up-regulation of uPA
resulted in a 1.6-fold increase in HBMMuPAR production
(P  .043); almost 1.6-fold decrease in PAI-1 production
(P  .011); and a greater than twofold decrease in PAI-2
production (P  .005) compared with ad-blank controls.
No significant difference between ad-blank and baseline
(carrier alone) control groups was shown for any of the
fibrinolytic mediators measured (Table I).
Five of 10 cytokines analyzed were detectable (IL-8,
IL-6, IFN-, RANTES, GM-CSF), and the expression of
these cytokines was not significantly different between
baseline and cells treated with ad-uPA or ad-blank (Table
n blood-derived monocyte/macrophages transfected with
e
nk Baseline
Ad-blank vs
ad-uPA, P
Ad-blank vs
baseline, P
0.08 (0) .003 .90
0.5 (0) .0001 .90
43) 4061 (1264) .043 .68
23 (7) .011 .17
97) 3789 (745) .005 .07
A, urokinase-type plasminogen activator; uPAR, urokinase plasminogen
ls.uma
alon
d-bla
8 (0)
5 (0)
0 (12
7 (6)
3 (10
r-1; uP
ividuaII). Levels of IL-1, IL- 1, TNF-, IL-4, and IL-10
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activity could not be measured in untreated (baseline)
cells or cells treated with ad-uPA.
Effect of monocyte uPA up-regulation on in vitro
MM6 and HBMM migration. Transduction with ad-
uPA resulted in a more rapid migration ofMM6 cells across
fibrin-coated filters (11%  1.4%) compared with ad-
blank–treated cells (5%  0.6%, P  0.005, Fig 1). Treat-
ment with ad-uPA also resulted in the accelerated move-
ment of HBMMs cells across fibrin-coated filters (70% 
8.9%) compared with ad-blank–treated cells (54%  9.8%,
Table II. Expression of cytokines by primary human
blood-derived monocytes/macrophages transfected with
ad-uPA, ad-blank, and baseline cells treated with carrier
alone
Cytokinea Ad-uPA Ad-blank Baseline
RANTES, pg/mg sol
protein 256 (99) 261 (101) 180 (73)
IL-8, ng/mg sol
protein 63 (36) 50 (28) 46 (23)
IFN-, pg/mg sol
protein 391 (135) 314 (100) 355 (123)
Il-6, pg/mg sol
protein 2887 (1886) 2456 (1575) 1889 (1245)
GM-CSF, pg/mg sol
protein 792 (333) 739 (283) 579 (225)
Ad, Adenovirus; GM-CSF, granulocyte macrophage-colony stimulating fac-
tor; IL, interleukin; INF, interferon; RANTES, regulated upon activation
normal T-cell expressed and secreted; uPA, urokinase-type plasminogen
activator.
aData are expressed as mean (standard error of the mean) of 12 healthy
individuals.
Fig 1. Migration of MM6 cells treated with either adenovirus
(ad) expressing urokinase-type plasminogen activator (ad-uPA)
or ad-blank across a fibrin matrix (n  5). Each experiment was
performed in quintuplicate (bars represent means). Transfection
with ad-uPA resulted in a more rapid migration of MM6 cells
across fibrin-coated filters (11% [standard error of the mean,
1.4%]) compared with ad-blank–treated cells (5% [standard error
of the mean, 0.6%], P  .005).P  .03, Fig 2).Characterization of thrombus resolution in SCID
mice. Laminar thrombi were successfully formed in all
mice with no complications. There was no difference in the
thrombus size between the SCID mice and their wild-type
controls at 24 hours (11.4  0.8 vs 12.3  1.6mm2), 1
week (10.2  1.7 vs 12.9  1.3 mm2), 2 weeks (2.5 0.6
vs 5.5  2.3 mm2), or 3 weeks (1.7  0.3 vs 1.6  0.7
mm2; two-way ANOVA, P  .1, n  8/group); ad hoc
post-testing also showed no difference in thrombus size at
any time interval. The number and distribution of neutro-
phils in the infiltrate that occurred during thrombogenesis
was similar in the SCID mice (8.4%  0.8% of thrombus
area compared with 7.1%  1% in wild type controls, P 
.1, n  8/group). There was also no difference in the area
of thrombus recanalization or the number of infiltrating
monocytes found in the two groups during resolution
(ANOVA, P  0.1, n  8/group).
No difference was found in the speed and size of vein
lumen recanalization between the SCID and their wild-
type controls at 1 week (3.5  0.5 vs 5.4  1.0 mm2), 2
weeks (11.4 1.3 vs 11.3 1.4 mm2), or 3 weeks (22.9
1.8 vs 21.9  1.7 mm2; two-way ANOVA, P  0.1).
Tracking of injected HBMMs. More than 90% of
HBMMs were labeled with PKH2. Fluorescently labeled
(PKH2) HBMMs were present in the thrombus at 7 days
after intravenous injection. There was negligible fluores-
cence in the vein wall at this time. The PKH2-labeled cells
costained positively for HLA (Fig 3).
Effect of monocyte uPA up-regulation on throm-
bus resolution. No evidence of any immune rejection was
noted, and animals appeared to be healthy for the duration
of the study. No pathologic bleeding or premature deaths
occurred. Systemic injection of uPA-upregulated HBMMs
Fig 2. Migration of primary monocytes treated with either ade-
novirus (ad) expressing urokinase-type plasminogen activator (ad-
uPA) or ad-blank across a fibrin matrix (n 10). Each experiment
was performed in triplicate (Bars representmeans). Treatment with
ad-uPA also resulted in the accelerated movement of cells across
fibrin-coated filters (70% [standard error of the mean, 8.9%])
compared with ad-blank–treated cells (54% [standard error of the
mean, 9.8%], P  .03).reduced thrombusweight at 7 days by about 20% (9.0 0.52
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mg, P .038) and control animals injected with carrier alone
(13.3 1.08 mg, P .0028, Fig 4).
DISCUSSION
To our knowledge, this is the first report to show that
adenovirus-mediated up-regulation of uPA in monocytic
cells reduces the weight of experimentally induced venous
thrombi. Transduction of HBMMs with ad-uPA resulted
in150-fold increase in uPA-mediated fibrinolytic activity
compared with ad-blank–transfected cells, without affect-
ing their viability or inflammatory responses in vitro. The
increased uPA activity was observed 4 days after transduc-
tion in vitro.We have previously shown that direct injection
of the construct used in this study results in increased uPA
activity in the thrombus for at least 7 days,11 while others
have reported that this construct expresses active uPA for at
least 14 days in vivo.13
The increased fibrinolytic activity of ad-uPA up-
regulated HBMMs was also associated with a modest but
significant rise in the expression of uPAR and a reduction in
PAI-1 and PAI-2 protein levels. The higher levels of soluble
Fig 3. Recruitment of systemically injected monocyt
Immunohistochemical staining human leukocyte anti
cence. D, Composite staining of PKH-labeled huma
magnification 400).uPAR produced by the cells treated with ad-uPA may havereflected the cleavage of uPAR at the cell surface by the
increased amounts of uPA expressed. Urokinase mediates
the cleavage of uPAR as part of a negative feedback mech-
anism to regulate activation of plasminogen on the surface
of monocytic cells.24 The reduced levels of PAI-1 and
PAI-2 cannot be explained by the inability of the ELISAs to
discriminate between PAI:uPA complexes, because there
was no difference in the ELISA signal generated after the
addition of excess PAI to a standard amount of uPA com-
pared with uPA alone (data not shown). The reduced
expression of both PAI-1 and PAI-2 after transduction
with the ad-uPA construct may have been the result of
their internalization by endocytosis after inhibition of
uPA:uPAR complexes by either of these PAIs.25 Levels
of the uPAR would be less affected by this process as it is
subsequently recycled to the cell surface.25
Treatment of isolated HBMMs with ad-uPA did not
appear to induce an inflammatory response. This finding is
similar to that obtained after ad-tPA transduction of human
mononuclear cell isolates26 but contrasts with studies on
the effect of general adenoviral infection on mononuclear
cell responses.27 It is difficult, however, to compare these
the thrombus. A, Nuclear stain, blue fluorescence. B,
red fluorescence. C, PKH2-labeled cells, green fluores-
nocytes with antihuman leukocyte antigen (originales in
gen,
n mostudies because there are a number of differences in the
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cell pre-treatments that may affect the expression of inflam-
matory mediators by macrophages. Some of the cytokines
assessed in this study could not be measured because they
fell below the sensitivity of their respective assays. It is
possible that there were minor differences between treat-
ments that we could not detect. No difference was found
between ad-uPA, ad-blank, or uninfected cells in the levels
of inflammatory cytokines that were measurable.
The model of venous thrombosis in the SCID mouse
was based on our previous mouse models.10,11 Thrombus
formation was highly reproducible, whereas the pattern of
resolution was similar to that seen in wild-type controls,
suggesting that lymphocytes do not participate in throm-
bus organization. The absence of lymphocytes did not
appear to affect the number and distribution of other
leukocytes found within the resolving thrombi. Neutro-
phils, which are the most common type of inflammatory
cells found in the thrombus at an early stage after its
formation,28 were present in similar numbers in the SCID
mice and their wild-type controls. Neutrophils have both
fibrinolytic29 and antifibrinolytic activity30 that appears to
regulate thrombus size.28
A similar temporal and spatial distribution of monocyte
recruitment and revascularization was also seen in the
thrombi produced in SCID mice compared with their
wild-type controls. The model allowed us to use human
monocytes, which are more easily isolated, in larger num-
bers and with greater purity than rodent monocytes. This
negated the use of large numbers of donor animals.
Because the binding of uPA to its receptor is species
specific, it was necessary to transduce the HBMMs with the
human uPA gene.13 A weakness in this approach is that
although human uPA can activate mouse plasminogen, it
Fig 4. Intravenous injection of adenovirus (ad) urokinase-type plas-
minogen activator (uPA) up-regulated human blood monocyte-
derived macrophages (HBMMs) reduced thrombus weight at 7
days by approximately 20% (9.0 mg [standard error of the mean]
0.52 mg) compared with either ad-blank–treated HBMMs (11.0
mg [standard error of the mean, 0.74 mg] P  .038) or control
animals injected with carrier alone (13.3 mg [standard error of the
mean, 1.08], P .0028). N 8 in each group. The bars represent
means.does this with less efficiency than human plasminogen (datanot shown). The use of murine cells up-regulated with
murine uPA was, however, precluded because the isolation
of pure populations of these cells in sufficient numbers was
not possible. It is conceivable, however, that a larger effect
on thrombus size might have been achieved if murine
macrophages upregulated for murine uPA had been used.
We have previously demonstrated that direct injection
of macrophages into the thrombus significantly reduces
thrombus size.31 These cells may stimulate resolution by
expressing a variety of enzymes, growth, and chemotactic
factors that stimulate organization and recanalization.7,32
Our previous work has shown that systemically injected
rodent mononuclear cells are recruited into resolving
thrombus.7 This study provides evidence that systemically
injected human monocytes (HBMMs) are also recruited
into the thrombus and that up-regulating uPA expression
in these cells results in enhanced resolution. There are
several plausible explanations for this effect:
First, uPA accelerated monocyte migration and deliv-
ered fibrinolytically active monocytes much earlier to the
thrombus. The in vitro studies showed a faster migration
rate for both HBMMs and MM6 cells transfected with
ad-uPA, confirming the work of others.33
Urokinase has a well-documented action on surface
proteolysis, cell adhesion, chemotaxis, and migration and
these effects have been noted both in vitro and in
vivo.10,33,34 Mice lacking the uPA gene fail to recruit cells
(monocytes in particular) into the thrombus.10 Urokinase-
dependent conformational change in uPAR mediates cy-
toskeletal changes, activation of kinases, and directional cell
migration.34 Urokinase also generates plasmin by cleaving
the proenzyme plasminogen. Plasmin is not only fibrino-
lytic but also activates other proteases that are crucial for
cell migration in tissues.35
Reliable quantification of the numbers of HBMMs
recruited was, however, difficult because of the back-
ground fluorescence associated with this label. Attempts at
quantifying HBMM numbers using reverse transcription-
polymerase chain reaction were not successful. Better meth-
ods of tracking injected monocytes using reporter gene tech-
nology in combination with imaging methods such as single
photon emission computed tomography (SPECT/CT) or
micro-PET would allow a sensitive, noninvasive (longitu-
dinal), quantitative tracking of injected ad-uPA-transduced
monocyte recruitment during resolution.
Secondly, these cells may have promoted resolution by
enhanced fibrinolysis mediated by the extra uPA generated
within the thrombus. This is in keeping with our previous
work showing that the induction of picogram quantities of
uPA activity within the thrombus (generated from direct
ad-uPA injection) is sufficient to increase the resolution of
the thrombus.11
Thirdly, it is also possible that ad-uPA-transduced
monocytes accelerated resolution through other mecha-
nisms that could include increasing endogenous monocyte
influx by releasing chemotactic cytokines at an early stage in
resolution.
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tracking both endogenous and exogenously administered
monocytes would help to define how these cells exert their
effect on thrombus resolution.
Altered macrophages have been used therapeutically in
humans for the treatment of malignant disease36 and might
also be used as gene delivery vehicles because they have a
natural tendency to migrate to the site of disease, such as
the thrombus. Using cells that have been altered by ex vivo
manipulation may obviate some of the problems of admin-
istering virus alone, including rapid loss to the liver and lack
of penetration into tissue.12 Targeting transduction to
circulating monocytes may also be possible by coating the
viral particles with sugars that bind to specific receptors on
these cells.37 This would prevent loss of the adenovirus to
the liver after systemic administration.
One study suggested that up-regulation of macrophage
uPA might enhance atherogenesis,38 but that study was
done in animals whose macrophages constitutively over-
expressed uPA. The method of uPA up-regulation used in
this study is transient (approximately 15 days) and is there-
fore unlikely to cause long-term problems.
Further studies are required to determine whether:
1. the time of delivery of the fibrinolytically overactive
macrophages to the thrombus is important;
2. injected monocytes enhance resolution directly or indi-
rectly by promoting endogenous monocyte recruit-
ment;
3. the effect of concomitantly up-regulating other factors,
known to increase uPA activity, such as its substrate
plasminogen could enhance their ability to resolve
thrombus;
4. the use of more powerful viral promoters that generate
higher and more sustained levels of uPA production
have greater efficacy; and
5. it is possible to reduce loss of injected cells to other
tissue sinks.
CONCLUSIONS
This study provides evidence that up-regulating mono-
cyte uPA enhances thrombus resolution. Our previous
studies have shown that thrombus resolution can be en-
hanced through the direct injection of monocytes7,31 or
adenovirus constructs over-expressing uPA11 or vascular
endothelial growth factor.23 Increasing the circulating con-
centrations of monocyte chemotaxins and angiogenic
agents may be counterproductive because they could re-
duce recruitment of monocytes and other cells important in
thrombus organization by overwhelming chemotactic gra-
dients. Monocytes could act as vectors that allow more
specific targeting of the thrombus. The proteins that are
up-regulated and the means by which this is achieved
would obviously require refinement.
There is also increasing evidence to suggest that mac-
rophages display phenotypic heterogeneity, with at least
two subtypes that are associated with either proinflamma-
tory activity (M1-type macrophages) or remodelling (M2-type) processes.39 All monocytes isolated and used in this
study were pretreated with MCSF, which is thought to
induce an M2 phenotype.40 We do not know, however,
whether viral transduction or the thrombus milieu had an
effect on this.
The development of any treatment that uses exogenous
altered cells, promotes their number through bone marrow
stimulation, or alters the activity of endogenous circulating
cells will rely on a better understanding of how these
phenotypes contribute to thrombus resolution.
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